J Nucl Cardiol. 2026 May;59S:102724. doi: 10.1016/j.nuclcard.2026.102724. Epub 2026 May 15.
ABSTRACT
Cardiac amyloid radionuclide imaging (CARI) with single-photon emission computed tomography (SPECT) bone-avid tracers plays a key role in the noninvasive detection of transthyretin cardiac amyloidosis (CA). In addition, newer amyloid-binding tracers used with positron emission tomography (PET) can identify different types of CA. These SPECT and PET CARI techniques generate "hot-spot" images that represent tracer accumulation in regions of amyloid deposition and are typically interpreted visually by comparing myocardial uptake with reference regions such as bone or the blood pool. Although qualitative interpretation of SPECT CARI has been effective for diagnosis, it has notable limitations. This review focuses on methods for quantitative SPECT and PET CARI, emphasizing the need for standardization and its potential role in early detection of cardiac amyloidosis, evaluation of disease burden, risk prediction, and longitudinal monitoring of disease progression.
PMID:42142945 | DOI:10.1016/j.nuclcard.2026.102724